Open Actively Recruiting

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3)

About

Brief Summary

This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage IIIb-IV cutaneous melanoma whose disease progressed on an anti PD-1 and an anti-CTLA-4 containing regimen (administered either as a combination regimen or in sequence) or who are not candidates for treatment with an anti-CTLA-4 therapy.

Primary Purpose
Treatment
Study Type
Interventional
Phase
Phase 3

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
12 Years
Maximum Age
N/A

Key Inclusion Criteria:

Key Exclusion Criteria:

Join this Trial

Share:
Study Stats
Protocol No.
24-5279
Category
Melanoma (Skin Cancer)
Contact
MARIA ZAMUDIO
Location
  • UCLA Westwood
For Providers
NCT No.
NCT06264180
For detailed technical eligibility, visit ClinicalTrials.gov.